Pasithea Therapeutics Corp. (KTTAW) Common Equity (2020 - 2026)

Pasithea Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $49.8 million for Q2 2026.

• In Q2 2026, Common Equity rose 228.36% year-over-year to $49.8 million; the TTM figure through Jun 2026 stood at $49.8 million (up 228.36% YoY), while the FY2025 annual figure was $55.2 million, up 273.54% from the prior year.
• Common Equity came in at $49.8 million for Q2 2026 at Pasithea Therapeutics, down from $54.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $55.2 million in Q4 2025 to a low of $12.2 million in Q3 2025.
• Average Common Equity over 5 years is $32.6 million, with a median of $32.0 million recorded in 2023.
• Year-over-year, Common Equity soared 10817.73% in 2022 and slumped 54.55% in 2024.
• Over 5 years, Common Equity stood at $42.5 million in 2022, then slumped by 44.94% to $23.4 million in 2023, then plunged by 36.82% to $14.8 million in 2024, then jumped by 273.54% to $55.2 million in 2025, then slipped by 9.74% to $49.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $49.8 million in Q2 2026, $54.8 million in Q1 2026, and $55.2 million in Q4 2025.